Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)

Sponsor
University Hospital, Bordeaux
Study ID
NCT06022328
Status
Recruiting
Apply to this trial

Conditions

  • Myeloproliferative Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Assessment of the epigenetic age — BIOLOGICAL
    Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis

Study Details

Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. MPN can be complicated by thrombosis and evolution into more aggressive diseases (myelofibrosis and acute leukemia). Aging remains the principal factor determining patients' survival in MPN. In recent years, DNA methylation has appeared as a mean to measure aging via the development of epigenetic clocks that have also been associated with the occurrence of thrombosis and cancer. The epiC project aims at determining epigenetic age of MPN patients and search for an association between this parameter and thrombotic/hematological complications.

Key Dates

First listed
Sep 1, 2023
Start date
Dec 15, 2023
Status verified
Jul 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
120 participants (estimated)

Arms

  • Arm: Patients with ET
    45 patients with ET: * 15 without thrombotic event (neither at diagnosis nor during follow-up) * 15 with thrombotic events (thrombosis at diagnosis or within 2 years of diagnosis) * 15 who progressed to myelofibrosis or AML during follow-up
  • Arm: Patients with PV
    45 patients with PV * 15 without thrombotic event (neither at diagnosis nor during follow-up) * 15 with thrombotic event (thrombosis at diagnosis or within 2 years of diagnosis) * 15 who progressed to myelofibrosis or AML during follow-up
  • Arm: Patients with PMF
    20 patients with PMF: * 10 without transformation into AML * 10 patients who progressed to AML
  • Arm: Patients without MPN
    10 patients without MPN

Primary Outcome Measure

Accelerated ageing of patients [ Time Frame: At inclusion, up to 1 year after diagnosis ]

Central Contacts

Related Studies